Search Results - "Naturale, M D"

Safety Profile of PCSK9 Inhibitors in Clinical Practice: An Italian Prospective Pharmacovigilance Study by Gagliardi, A, Palleria, C, Naturale, M D, de Francesco, A E, Leporini, C, Muraca, L, Rania, V, Tallarico, M, Pisano, M, Sarro, C D, Leo, A, Citraro, R, Gallelli, L, Sarro, G D

“…Introduction: Primary hypercholesterolemia, which is not adequately controlled with the continued use of statins at the maximum allowed dose is a serious…”
Get full text

4CPS-389 Governance of clinical trials between health needs, access to care, innovation and sustainability in the COVID-19 pandemic era by De Fina, M, Zito, M, Naturale, MD, Esposito, S, Monopoli, C, De Francesco, A

“…Background and importanceIn the constantly evolving new regulations for clinical trials, the hospital pharmacist is more and more involved in clinical trials.1…”
Get full text

4CPS-254 A retrospective study of antimicrobial stewardship in a university hospital by De Francesco, A, Zito, M, Esposito, S, Monopoli, C, Naturale, MD, De Fina, M

“…Background and importanceMisuse and abuse of antibiotics are among the main causes of the increase in antibiotic resistance. Monitoring and evaluation of…”
Get full text

4CPS-231 Real world data of monoclonal antibodies for the treatment of hyperlipidaemia: analysis 3 years after introduction in clinical practice by Naturale, MD, De Fina, M, Zito, M, Esposito, S, Monopoli, C, De Francesco, A

“…Background and importanceHyperlipidaemia is the main risk factor for the early manifestations of atherosclerosis and related complications. In recent years,…”
Get full text

5PSQ-065 Be a human, not a case report: hospital pharmacists make the difference by Brescia, A, Naturale, MD, Marrazzo, GM, Casuscelli, D, Spinoso, B, Esposito, S, Monopoli, C, Zito, M, de Francesco, A

“…Background and ImportanceThe hospital pharmacy of our Health Institute is eligible to carry out phase 1 study till 2017. In July 2021 a multidisciplinary team,…”
Get full text

Implementing a simple pharmacovigilance program to improve reporting of adverse events associated with biologic therapy in rheumatology: Preliminary results from the Calabria Biologics Pharmacovigilance Program (CBPP) by Palleria, Caterina, Iannone, Luigi, Leporini, Christian, Citraro, Rita, Manti, Antonia, Caminiti, Maurizio, Gigliotti, Pietro, Grembiale, Rosa Daniela, L'Andolina, Massimo, Muccari, Giuseppe, Naturale, Maria Diana, Olivo, Domenico, Pagano Mariano, Giuseppa, Pellegrini, Roberta, Varcasia, Giuseppe, Abdalla, Karim, Russo, Emilio, Ursini, Francesco, De Sarro, Giovambattista

“…Post-marketing surveillance activities (namely pharmacovigilance) are crucial to favor the early detection of unexpected adverse events (AEs) and/or serious…”
Get full text

5PSQ-152 Real world efficacy and cost data on patients with metastatic non-small cell lung cancer treated with checkpoint inhibitors in an Italian university hospital in September 2016–2020 by Veraldi, M, Esposito, S, Zito, C, Monopoli, C, Naturale, MD, De Francesco, AE

“…Background and importanceNon-small cell lung carcinoma (NSCLC) accounts for 85–90% of all forms of lung cancer. In recent years, the development of immune…”
Get full text

5PSQ-028 The governance of PCSK9-inhibitors for the treatment of primary hypercholesterolaemia: appropriateness analysis by Garreffa, MR, Zito, C, Esposito, S, Monopoli, C, Naturale, MD, de Francesco, AE

“…BackgroundRecently the European Medicines Agency approved Alirocumab and Evolocumab, two monoclonal antibodies against PCSK9 (PCSK9-inhibitors), a key protein…”
Get full text